The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma.
 
Paul Eliezer Oberstein
Consulting or Advisory Role - Merck; Purdue Pharma; Purdue Pharma
Research Funding - Aduro Biotech (Inst); Celgene (Inst); Halozyme (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Beth Schrope
No Relationships to Disclose
 
Tamas Gonda
No Relationships to Disclose
 
Amrita Sethi
Consulting or Advisory Role - Boston Scientific; Olympus Medical Systems
Patents, Royalties, Other Intellectual Property - Biliary sampling catheter
Travel, Accommodations, Expenses - Boston Scientific; Olympus Medical Systems
 
Arnold Han
No Relationships to Disclose
 
Gary K. Schwartz
Honoraria - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics
Consulting or Advisory Role - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Manish A. Shah
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Lilly/ImClone (Inst); Merck (Inst); Sanofi/Regeneron (Inst)